US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.90 -0.05 (-0.42%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Elects Kathleen Tregoning to Board of Directors
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins ↗
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass (CMPS) Q1 2026 Earnings Transcript ↗
Compass (CMPS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways Q1 Earnings Call Highlights ↗
Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for... 
Via MarketBeat
Topics Cannabis Earnings Government
News headline image
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
Via MarketBeat
Topics Government
News headline image
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
From Compass Pathfinder Limited
Via Business Wire
News headline image
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About ↗
Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression. 
Via The Motley Fool
Topics Government
News headline image
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
From Compass Pathfinder Limited
Via Business Wire
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
Via Chartmill
News headline image
Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research
Via AB Newswire
News headline image
This 4/20, Wall Street Is Betting on More Than Marijuana ↗
Via MarketBeat
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
This Psychedelic Biotech Stock Is Soaring After Trump Executive Order ↗
COMPASS Pathways PLC (NASDAQ:CMPS) shares are soaring on Monday after President Donald Trump issued an executive order directing federal health agencies to speed up the review process for... 
Via Benzinga
Topics Government
What's going on in today's session ↗
Via Chartmill
News headline image
Why Compass Pathways Stock Rocketed 40% Today ↗
Compass Pathways may be the first to benefit from an accelerated approval process. 
Via The Motley Fool
Topics Government
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
From Compass Pathfinder Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >